Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Measles Vector-based COVID-19 Vaccine (V591) in Healthy Volunteers
NCT04497298Phase 1Completed
- Sponsor
- Institut Pasteur
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Viral Vector Vaccines
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of V591 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Institut Pasteur. Primary endpoint: Safety and tolerability of the COVID-19 vaccine at Day 210. Started Aug 2020; status: completed.
02
Drugs
V591
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04497298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497298.